Continuation project for follow-up study of unvaccinated and Human papillomavirus (HPV) Type 16 vaccinated individuals will follow up to 9,000 women for up to five years through a one-year base award and four option periods.
Enrollment, including entry exams, for both control and vaccinated groups will be complete, except for a <10% subset of women whose enrollment period is ongoing, prior to award. Prior experience with the group includes a retention rate of greater than 90% which may be expected to continue in the upcoming award period. Approximately 90%of the group are sexually active and will require pelvic exams as part of the follow-up study. At the time of entry, unvaccinated women were provided information on the efficacy and benefits of the vaccine as part of the informed consent and the optimal care for this age group that consists of cervical cancer screening with cervical cytology and HPV testing will be followed.
Trayectoria: For more than 10 years I have worked at Proyecto Epidemiológico Guanacaste-Fundación INCIENSA in Costa Rica, and my work has been mainly related to plan, supervise and conduct the field efforts of several studies on HPV and cervical cancer epidemiology that have been conducted in collaboration with the US National Cancer Institute. From 2012 to 2014 I was at the International Agency for Research on Cancer were I expanded my area of research to gastric cancer and helicobacter pylori infection and started two large multicentric studies one in cervical cancer and one in gastric cancer and also initiated several collaborations with other scientists and groups within the Agency as well as in many Latin American countries. I have participated in the preparation and publication of several articles on peer-reviewed international indexed journals about HPV and cervical cancer in the last 8 years. SponsorNational Cancer Institute, USA
Correo electrónico: pgonzalez@acibcr.com
Teléfono: +506 2668 1128
Se inicio exitosamente la fase de salida de las paricipantes del protocolo y proximamente se publicaran los resultados finales del estudio.
01 de Marzo de 2012
http://www.nacion.com/vivir/medicina/Estudio-evaluara-vacuna-evita-papiloma_0_1563843621.html
N/A
En fase de salida de seguimiento.
